Sanofi and CD&R finalize the sale of Opella

On April 30, 2025, Sanofi and CD&R completed the sale of Opella, marking a major milestone for Sanofi as it refocuses on biopharmaceuticals. Opella becomes a major independent player in consumer healthcare. Sanofi retains a 48.2% stake and sells 50% to CD&R, which will support its development. Bpifrance holds a 1.8% stake. The transaction is worth approximately €10 billion in cash.

Opella, based in France, operates in 100 countries and employs over 11,000 people. With brands such as Allegra and Doliprane, it is the world's third largest OTC pharmaceutical company. This position is reinforced by an aging population and a greater focus on wellness.